Vaccine by Thyagarajan, Veena et al.
Identification of seizures among adults and children following 
influenza vaccination using health insurance claims data
Veena Thyagarajana,*, Sue Sua, Julianne Geeb, Jonathan Duffyb, Natalie L. McCarthyb, K. 
Arnold Chanc, Eric S. Weintraubb, and Nancy D. Lind
aOptum Epidemiology, 315 E. Eisenhower Parkway Suite 305, Ann Arbor, MI 48108, USA
bDivision of Healthcare Quality Promotion, Centers for Disease Control and Prevention, 1600 
Clifton Road NE, MS-D26, Atlanta, GA 30333, USA
cDepartment of Medical Research, National Taiwan University Hospital and National Taiwan 
University College of Medicine, Taipei, Taiwan
dOptum Epidemiology, 950 Winter Street Suite 3800, Waltham, MA 02451, USA
Abstract
Introduction: Post-licensure surveillance of adverse events following vaccination or prescription 
drug use often relies on electronic healthcare data to efficiently detect and evaluate safety signals. 
The accuracy of seizure-related diagnosis codes in identifying true incident seizure events in 
vaccine safety studies is influenced by factors such as clinical setting of diagnosis and age. To 
date, most studies of post-vaccination seizure have focused on pediatric populations. More 
information is needed on how well seizure can be identified in adults and children using 
algorithms that rely on electronic healthcare data.
Methods: This validation study was part of a larger safety study of influenza vaccination during 
the 2009–2010 and 2010–2011 influenza seasons. Children and adults receiving influenza 
vaccination were drawn from an administrative claims database of a large United States healthcare 
insurer. Potential seizure events were identified using an algorithm of ICD-9 diagnosis codes 
associated with an emergency department (ED) visit or hospitalization within pre-specified risk 
windows following influenza vaccination. Seizure events were confirmed through medical record 
review. The positive predictive value (PPV) of the algorithm was calculated within each diagnostic 
setting and stratified by age group, ICD-9 code group, and sex.
Results: Review confirmed 113 out of 176 potential seizure events. The PPVs were higher in the 
ED setting (93.9%) than in the inpatient setting (38.3%). The PPVs by age varied within the ED 
setting (98.2% in <7 years, 76.9% in 7–24 years, 92.3% in ≥25 years) and within the inpatient 
setting (64.7% in <7 years, 33.3% in 7–24 years, 32.3% in ≥25 years).
Conclusions: Our algorithm for identification of seizure events using claims data had a high 
level of accuracy in the emergency department setting in young children and older adults and a 
lower, but acceptable, level of accuracy in older children and young adults.
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1. Introduction
In Western Australia, an increased risk of febrile convulsions was reported in children under 
5 years of age following receipt of the 2010 trivalent inactivated influenza vaccine (TIV) 
manufactured by CSL Biotherapies (Fluvax®, Fluvax Junior®), leading to a temporary 
suspension of the Western Australia influenza vaccination program for children under 5 
years of age [1]. An elevated risk of febrile seizures was also reported in a large United 
States (US) cohort in the 0–1 days following first dose TIV during the 2010–2011 season 
and in other studies in the short term following administration of vaccinations including 
diphtheria, tetanus, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type 
B (DTaP-IPV-Hib), measles, mumps, rubella (MMR), and MMR plus varicella (MMRV) [2–
11]. These studies highlight the risk of seizures in children following vaccine-induced fever. 
Although post-vaccination seizure is less common in adults, seizure has been reported as an 
adverse event (AE) in adults following influenza vaccination [12], which prompted the 
inclusion of seizures in adults as an outcome of interest in prospective influenza vaccine 
surveillance previously done in the US [13]. Monitoring for seizures as a potential AE in 
post-licensure vaccine safety studies in all age groups contributes to the robustness of the 
safety monitoring of the US influenza immunization program.
Post-licensure active surveillance of AEs following vaccination or prescription drug use 
often relies on electronic healthcare data to efficiently and effectively detect and evaluate 
potential safety signals [14,15]. The efficiency and validity of these surveillance programs 
are increased with an algorithm that reliably identifies adverse events using diagnosis codes 
recorded for medical visits.
Performance of seizure-related diagnosis codes in postlicensure safety studies is variable and 
may be influenced by several factors, including clinical diagnostic setting and age [16–19]. 
A systematic review commissioned by the US Food and Drug Administration (FDA) to 
validate seizure, convulsion, or epilepsy cases as part of its Mini-Sentinel program pilot 
found positive predictive values (PPVs) ranging from 21% to 98% [16]. Many of the studies 
included in the review focused on the pediatric population. Few published studies in adult 
populations were identified. The PPV of diagnosis codes suggestive of seizure in a study of 
adult tramadol users within a large US health insurance plan was 21%. [19]. More 
information is needed on how well seizures among vaccinated adults and children can be 
identified using electronic healthcare data.
This study objective was to evaluate an algorithm for identification of seizure events using 
an administrative claims database in a large health plan population of adults and children 
who received influenza vaccination in the US during the 2009–2010 and 2010–2011 
seasons.
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2. Methods
2.1. Data source and study population
The study population was derived from an electronic healthcare database of a large US 
insurer developed for research purposes. Accessible information includes demographics and 
pharmacy, medical, and facility claims, which provide dates on services, procedures, and 
their accompanying diagnoses. The insured population from which the data are drawn is 
geographically diverse, comprising approximately 3–4% of the US population. For a subset 
of approximately 6 million health plan members with medical coverage and pharmacy 
benefits, patient-identifiable information (PII) may be accessed for further inquiries, 
including medical chart review. The data undergo regular audits and quality control 
procedures by the insurer and are updated monthly.
This validation study was nested within a cohort study evaluating risk for adverse events 
following influenza vaccination during the 2009–2010 and 2010–2011 seasons. Eligible 
cohort study subjects included commercial health insurance plan members with complete 
medical coverage and pharmacy benefits. Cohort members received monovalent 2009 H1N1 
or trivalent seasonal influenza vaccination from September 1 to March 31 during the 2009–
2010 or 2010–2011 season, were aged 6 months or older at the time of the vaccination, and 
had at least 9 months of continuous health plan enrollment prior to vaccination. Individuals 
with vaccinations during both seasons entered the analysis more than once. This validation 
study included cohort members with potential seizure events identified using the algorithm 
described below and with administrative ability to access PII for medical record review.
2.2. Privacy and confidentiality
Approval of the study protocol and waiver of patient authorization were obtained from the 
New England Institutional Review Board and affiliated Privacy Board.
2.3. Algorithm for identification of potential seizure events
Potential seizure events met the following criteria: (1) presence of insurance claims 
associated with an emergency department (ED) visit or inpatient hospitalization with 
International Classification of Diseases, 9th Revision (ICD-9) codes 345.xx1 (epilepsy) or 
780.3x1 (convulsions) occurring on days 0 through 29 following the index vaccination (day 
0 = day of vaccination), and (2) absence of any of these ICD-9 codes in the 42 days prior to 
the potential seizure event, irrespective of the time since influenza vaccination. The 
restriction to the first occurrence of the code in a 42-day period was used in a prior 
evaluation of seizure signals following influenza vaccination [2] and was applied in the 
safety study to improve specificity in identifying new seizure events (e.g., as opposed to 
follow up visits for a previous seizure) while still maintaining adequate sensitivity for signal 
detection and evaluation.
1The x represents any number.
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2.4. Verification of potential seizure events
A research nurse reviewed listings of claims for healthcare services and treatments 
surrounding the potential seizure event date to select a healthcare provider most likely to 
yield records with information necessary to confirm the potential seizure events. Where 
possible, two providers were selected for each potential case so an alternate could be 
contacted if the first choice provider declined to participate.
Following a request letter to the selected providers, which included copies of the IRB 
approval and waiver of patient authorization, trained abstractors contacted the providers to 
retrieve medical records. Information on patient demographics, clinical characteristics and 
history, and state of consciousness and motor manifestations at the time of the event was 
abstracted. As complete information was unavailable in most medical records to classify 
cases using Brighton Collaboration criteria [20], potential cases were classified by the 
abstractors into (1) definite, (2) possible, or (3) no evidence of seizure based on the clinician 
diagnosis documented in the medical record. Definite seizures had medical record 
documentation of a clinical diagnosis of a seizure event. Possible seizures had medical 
record documentation by the treating clinician noting a possible seizure with further 
documentation unavailable to confirm. For records with no documentation of a new seizure 
event, reason(s) for non-confirmation were ascertained.
2.5. Analysis
We calculated the positive predictive value (PPV) of the seizure algorithm as the number of 
definite seizure events divided by the number of medical records abstracted. For analytic 
purposes, medical records received without the requested date range of interest were not 
abstracted and not included in the PPV estimation. PPVs were calculated separately for the 
ED and inpatient settings and stratified by age group, gender, and ICD-9 diagnosis code 
groups (epilepsy and convulsion). These variables were previously observed to influence the 
PPV of claims-based seizure algorithms [16–19]. Patients with ED and inpatient claims on 
the day of the potential seizure were assigned to the inpatient setting. Patients were 
classified as children (<7 years), older children and young adults (7–24 years), and adults 
(≥25 years). As the study population includes patients administered monovalent 2009 H1N1 
influenza vaccination, 24 years of age was chosen as the cutoff point between young adults 
and adults for consistency with administration recommendations for that vaccine [21]. 
Children younger than 1 year of age were initially evaluated separately but later combined 
with children through 7 years of age due to small sample size. Exact 95% confidence 
intervals (CI) were calculated using the Clopper–Pearson method [22]. Data analyses were 
performed using SAS version 9.2 (SAS Institute, Cary, NC).
3. Results
224 potential seizure events following 1,091,181 influenza vaccinations were identified for 
medical record review in the main safety study and were thus eligible for inclusion in the 
algorithm validation analysis.
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3.1. Characteristics of potential seizure events
Characteristics of the 224 potential seizure events by age group are described in Table 1. 
Potential events with claims for only convulsions occurred most frequently in children 
(85.9%) compared with the other age groups. Potential events with claims for only epilepsy 
occurred most frequently in adults (40.4%) versus the other age groups. Potential events in 
the ED setting were identified most frequently in children (74.1%) versus the other age 
groups, while potential events in the inpatient setting were identified most frequently in 
adults (84.8%) versus the other age groups.
3.2. Medical record retrieval and abstraction
Of the 224 medical records requested, 176 (78.6%) were obtained and abstracted. 48 records 
were not obtained due to provider non-response or unavailability of records within the 
requested date range for administrative reasons. The number of charts available for 
abstraction is presented in Table 2. The proportion of charts obtained and abstracted was 
highest in children (85.9%). The proportion of charts obtained and abstracted was higher for 
the ED setting (84.5%) than the inpatient setting (74.0%). Of the 73 charts abstracted in 
children, 56 (76.7%) were obtained and abstracted from the ED setting.
3.3. PPVs by clinical care setting
Of the 176 charts abstracted, 113 (64.2%) were classified as definite new seizure events, 6 
(3.4%) were possible new seizure events, and 57 (32.4%) were non-seizure events.
The ED setting accounted for 82 (46.6%) of the 176 abstracted charts. The PPVs within the 
ED setting varied by age: 98.2% (95% CI: 90.5–100.0%) for seizure events in children, 
76.9% (95% CI: 46.2–95.0%) in older children and young adults, and 92.3% (95% CI: 64.0–
99.8%) in adults (Table 3). The PPV associated with the presence of claims for only 
convulsions varied by age group, with98.1% (95% CI: 89.7–100.0%) in children, 66.7% 
(95% CI: 22.3–95.7%) in older children and young adults, and 88.9% (95% CI: 51.8–99.7%) 
in adults. For the small number of subjects with both epilepsy and convulsion claims, the 
PPVs were 100.0% (95% CI: 75.3–100.0%) for all age groups.
94 charts (53.4%) were abstracted from the inpatient setting. The PPVs within the inpatient 
setting were lower than in the ED setting, and varied by age group: 64.7% (95% CI: 38.3–
85.8%) in children, 33.3% (95% CI: 9.9–65.1%) in older children and young adults, and 
32.3% (95% CI: 21.2–45.1%) in adults (Table 4). PPVs associated with claims for epilepsy 
alone varied by age group (100.0%, 95% CI:2.5–100.0% in children; 25.0%, 95% CI: 0.6–
80.6% in older children and young adults; 17.6%, 95% CI: 6.8–34.5% in adults), as did the 
PPVs associated with claims for convulsions alone (72.7%, 95% CI: 39.0–94.0% in 
children; 40.0%, 95% CI: 5.3–85.3% in older children and young adults; 54.2%, 95% CI: 
32.8–74.5% in adults) (Table 4). The PPVs did not improve with the presence of claims for 
both epilepsy and convulsions.
3.4. Availability of clinical information for definite seizure events
Information on motor manifestations, state of consciousness, and febrile status was 
abstracted from the medical records of the 113 definite seizure events. Information on motor 
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manifestations was missing from 30.3% of records for children, 14.2% of records for older 
children and young adults, and 33.3% of records for adults. Information on state of 
consciousness was missing from 72.7% of records for children, 42.9% of records for older 
children and young adults, and 57.6% of records for adults. The majority of records 
therefore did not have adequate information to classify definite seizure events using the 
Brighton Collaboration criteria. Data on febrile status based on report of fever at the time of 
seizure occurrence noted in the medical record or temperature of >38.0 °C (100.4 °F) 
recorded upon presentation at the ED or inpatient hospital was available in the majority of 
records; 84.8% of definite seizure events in children were likely febrile compared with only 
3% of definite seizure events in adults. No evidence of febrile seizure events were found in 
older children and young adults. When examining febrile status of definite seizure events by 
ICD-9 diagnosis code, 11.1% with claims for epilepsy only, 60.5% with claims for 
convulsions only, and 22.2% claims for both epilepsy and convulsions were likely to be 
febrile.
3.5. Reasons for non-confirmation among non-cases
Reasons for non-confirmation for the 57 non-seizure cases included one or more of the 
following: (1) visit for another reason, but the patient had documented history of seizure 
disorder (72.0%), (2) visits for seizure-related testing but not involving a seizure event on 
that day (i.e., seizure diagnosis claim was a justification for neurological tests such as 
electroencephalogram (EEG) or magnetic resonance imaging (MRI)) (21.0%), (3) visit for a 
suspected seizure that was ruled out (14.0%), and (4) indicated management of a known 
seizure disorder (7.0%). Of the 57 cases, 41 (72.0%) were in adults, 6 (10.5%) in children, 
and 10 (17.5%) in older children and young adults. Of the 41 adult cases, 34 (82.9%) had a 
visit for another reason but with a documented history of seizure disorder. No significant 
differences in reasons for non-confirmation were observed among the other age groups.
4. Discussion
This study validated an algorithm to identify seizures in vaccinated children and adults 
within a health insurance claims database using a combination of ICD-9 diagnosis codes, 
diagnostic setting, and pre-specified lookback and risk periods relative to vaccination. Our 
findings suggest higher PPVs with ICD-9 codes associated with ED visits (76.9–98.2%) and 
lower PPVs for the same claimsbased criteria when associated with inpatient visits (32.3–
64.7%). Lower PPVs were observed in older children and young adults in the ED setting and 
in older children and young adults and adults in the inpatient setting. The majority of non-
confirmed cases were in adults with a prior history of seizure disorder.
Previous studies within vaccinated populations relying on health insurance claims or 
electronic healthcare data have focused on performance of seizure diagnosis codes in 
children. Our pediatric population findings of higher PPVs in the ED setting and lower PPVs 
in the inpatient setting are consistent with findings by Shui and colleagues (2009), who 
reported a PPV of 97% in an ED setting and 64% in an inpatient setting in children aged 6–
23 months. The limited availability of Brighton Collaboration classification criteria 
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information and febrile status in medical charts is also consistent with previous findings 
[18,23].
The differences in PPVs by clinical care setting and age group are likely due to several 
factors. The higher PPVs in children may be a function of disease incidence and prevalence, 
as children, particularly under the age of 2, are at higher risk for a seizure event [24]. Most 
charts abstracted and confirmed in the ED setting were in children. Parents of a young child 
with a seizure are likely to seek immediate medical attention at an emergency department. 
Seizure diagnosis codes for older children and adults may represent a personal history of 
seizures and/or a follow-up visit rather than a new event. Of the 78 cases obtained in adults, 
65 were abstracted from an inpatient setting. The differences in PPV by diagnostic setting 
may be a function of the age of the health plan members and the underlying disease pattern 
in different age groups.
The PPVs by ICD-9 diagnosis code varied by age group within the ED and inpatient 
settings. Convulsion diagnosis codes are typically used to code isolated seizure events, while 
epilepsy codes are used to code recurrent seizure events [25]. This may be reflected in the 
higher PPVs with convulsions in children in both the ED (98.1%) and inpatient (72.7%) 
settings. The presence of epilepsy claims alone was rarely seen in the ED setting. The 
presence of epilepsy claims alone was seen more frequently in the inpatient setting, but gave 
rise to lower PPVs in older children/young adults and adults. In the small number of records 
with both epilepsy and convulsions claims, high PPVs were observed in the ED setting, but 
the presence of both codes did not consistently translate into higher PPVs in the inpatient 
setting. Since the diagnosis of seizures is generally made after the event occurs outside of 
the medical care setting, availability of clinical information in the Brighton collaboration 
classification scheme was limited in the medical record.
This study does have certain limitations. Approximately 15% of ED records and 26% of 
inpatient records were not procured due to provider non-response. The higher non-
procurement rate of inpatient records may be attributed to administrative barriers that are 
often present when requesting records from an inpatient hospital. To maximize abstraction 
rates, charts were procured from an alternate provider where possible if the first choice 
provider declined to participate. The small sample size precluded an assessment of 
predictors of definite seizures using a multivariate logistic regression model. All cohort 
members received influenza vaccination. Our findings are consistent with PPVs reported in 
other vaccinated health plan populations [18] and may therefore be useful to other vaccine 
safety studies. A brief evaluation of the PPVs in mutually exclusive time windows (0–1, 2–7, 
8–14, 15–29 days) following vaccination showed no variation based on time since influenza 
vaccination. As seizures occurring in later time windows could reasonably be attributed to 
non-vaccine exposures, the algorithm may also be useful in non-vaccine safety studies. This 
warrants further investigation.
This study examined the performance of an algorithm to identify seizure events in influenza-
vaccinated adults and children in a claims data environment. We restricted outcome 
identification in claims to ED and inpatient settings to improve specificity, as previous 
publications have reported low predictive values of diagnosis codes for seizures identified in 
Thyagarajan et al. Page 7
Vaccine. Author manuscript; available in PMC 2019 July 17.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
outpatient settings [16,18]. Our algorithm had a high level of accuracy in the ED setting in 
young children and older adults and a lower, but acceptable, level of accuracy in older 
children and young adults. This study adds to the literature supporting the reliability of 
electronic healthcare data in accurately identifying seizures associated with an ED visit. The 
low predictive value in the inpatient setting, particularly with epilepsy claims, suggests the 
continued need for medical record confirmation of claims-identified seizure events in this 
setting.
5. Conclusions
This study evaluated the performance of an algorithm to identify seizures in influenza-
vaccinated adults and children using health insurance claims data. This study adds to the 
literature supporting the reliability of electronic healthcare data in accurately identifying 
seizure events in the ED setting in vaccinated populations.
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Table 2
Number of charts available for abstraction.
Charts requested Complete charts obtained and abstracted
N N %
Overall 224 176 78.6
Age
 <7 years 85 73 85.9
 7–24 years 40 25 62.5
 ≥25 years 99 78 78.8
Setting of diagnosis
 ED 97 82 84.5
 Inpatient 127 94 74.0
Sex
 Male 115 88 76.5
 Female 109 88 80.7
ICD-9 diagnosis codea
 345.xx only 56 41 73.2
 780.3xx only 136 107 78.7
 Both 345.xx and 780.3x 32 28 87.5
aCodes included all digits. ICD-9 345.xx = epilepsy, ICD-9 780.3x = convulsions.
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